The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization.
10.5468/ogs.2014.57.3.216
- Author:
Kyung Hee LEE
1
;
Chung Hoon KIM
;
Hye Jin SUK
;
You Jeong LEE
;
Su Kyung KWON
;
Sung Hoon KIM
;
Hee Dong CHAE
;
Byung Moon KANG
Author Information
1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. chnkim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Gonadotrophin-releasing hormone antagonist;
In vitro fertilization;
Letrozole;
Poor responder
- MeSH:
Abortion, Spontaneous;
Aromatase*;
Cohort Studies;
Embryo Implantation;
Embryo Transfer;
Female;
Fertilization in Vitro*;
Follicle Stimulating Hormone, Human;
Gonadotropin-Releasing Hormone;
Humans;
Oocytes;
Ovulation Induction;
Pregnancy;
Pregnancy Outcome;
Pregnancy Rate;
Retrospective Studies
- From:Obstetrics & Gynecology Science
2014;57(3):216-222
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate whether letrozole incorporated in a gonadotrophin-releasing hormone (GnRH) antagonist multiple dose protocol (MDP) improved controlled ovarian stimulation (COS) and in vitro fertilization (IVF) results in poor responders who underwent IVF treatment. METHODS: In this retrospective cohort study, a total of 103 consecutive IVF cycles that were performed during either the letrozole/GnRH antagonist MDP cycles (letrozole group, n=46) or the standard GnRH antagonist MDP cycles (control group, n=57) were included in 103 poor responders. COS results and IVF outcomes were compared between the two groups. RESULTS: Total dose and days of recombinant human follicle stimulating hormone (rhFSH) administered were significantly fewer in the letrozole group than in the control group. Duration of GnRH antagonist administered was also shorter in the letrozole group. The number of oocytes retrieved was significantly higher in the letrozole group. However, clinical pregnancy rate per cycle initiated, clinical pregnancy rate per embryo transfer, embryo implantation rate and miscarriage rate were similar in the two groups. CONCLUSION: The letrozole incorporated in GnRH antagonist MDP may be more effective because it results comparable pregnancy outcomes with shorter duration and smaller dose of rhFSH, when compared with the standard GnRH antagonist MDP.
